(NASDAQ: BEAM) Beam Therapeutics's forecast annual revenue growth rate of -6.94% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.33%.
Beam Therapeutics's revenue in 2025 is $63,578,000.On average, 5 Wall Street analysts forecast BEAM's revenue for 2025 to be $5,102,870,292, with the lowest BEAM revenue forecast at $3,004,645,969, and the highest BEAM revenue forecast at $8,295,960,255. On average, 4 Wall Street analysts forecast BEAM's revenue for 2026 to be $4,594,151,954, with the lowest BEAM revenue forecast at $37,206,125, and the highest BEAM revenue forecast at $11,061,280,340.
In 2027, BEAM is forecast to generate $5,449,792,266 in revenue, with the lowest revenue forecast at $136,757,648 and the highest revenue forecast at $12,066,851,280.